Aripiprazole

• 

  Subject Areas on Research

  • A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). 
  • A pilot randomized placebo-controlled trial of adjunctive aripiprazole for chronic PTSD in US military Veterans resistant to antidepressant treatment. 
  • A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). 
  • A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. 
  • A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies. 
  • A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. 
  • A retrospective study exploring the effects of intramuscular aripiprazole on QTc change in agitated medically ill patients. 
  • Advances in Pharmacotherapy of Late-Life Depression. 
  • An open-label pilot study of aripiprazole for male and female veterans with chronic post-traumatic stress disorder who respond suboptimally to antidepressants. 
  • Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. 
  • Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting. 
  • Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. 
  • Aripiprazole for Post-traumatic Stress Disorder: A Systematic Review. 
  • Aripiprazole for agitation in a 13-year-old girl with neuroleptic malignant syndrome. 
  • Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. 
  • Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment. 
  • Aripiprazole: pharmacology, efficacy, safety and tolerability. 
  • Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. 
  • Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. 
  • Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison. 
  • Comparison of academic and nonacademic sites in multi-center clinical trials. 
  • Deletion of GSK3β in D2R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium action. 
  • Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. 
  • Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. 
  • Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. 
  • Exacerbation of psychotic disorder during pregnancy in the context of medication discontinuation. 
  • Implications of atypical antipsychotic prescribing in the intensive care unit. 
  • Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study. 
  • Results of phase 3 of the CATIE schizophrenia trial. 
  • Safety of antipsychotics in the setting of QTc prolongation: the utility of the JT index. 
  • Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists. 
  • The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. 
  • The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression. 
  • The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. 
  • Use of aripiprazole in a patient with multiple sclerosis presenting with paranoid psychosis.